Figure 2.
Food and Drug Administration approvals summary for immune checkpoint inhibitors based on microsatellite instability and tumor mutational burden status in solid tumors. *KEYNOTE-16; **KEYNOTE-158; ***KEYNOTE-146 and KEYNOTE-775; §CheckMate142; !Garnet. CRC, colorectal cancer; dMMR, deficient mismatch repair; MSI-H, microsatellite instability-high; MSS, microsatellite stable; TMB, tumor mutational burden.